New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.

ABSTRACT: The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research is focused on the development of oral therapies with improved efficacy and safety compared with available alternatives, as exemplified by deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for the treatment of moderate to severe psoriasis in adults. Recent advances in our knowledge of psoriasis pathogenesis have also led to the development of targeted topical molecules, mostly focused on intracellular signaling pathways such as AhR, PDE-4, and Jak-STAT. Tapinarof (an AhR modu

SUBMITTER: Carmona-Rocha E 

PROVIDER: S-EPMC10892104 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature